117 related articles for article (PubMed ID: 36560517)
1. The Inhibition of SARS-CoV-2 and the Modulation of Inflammatory Responses by the Extract of
Rather IA; Lew LC; Kamli MR; Hakeem KR; Sabir JSM; Park YH; Hor YY
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560517
[TBL] [Abstract][Full Text] [Related]
2. Potential Adjuvant Therapeutic Effect of
Rather IA; Choi SB; Kamli MR; Hakeem KR; Sabir JSM; Park YH; Hor YY
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696175
[TBL] [Abstract][Full Text] [Related]
3. Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study.
Rather IA; Kim BC; Lew LC; Cha SK; Lee JH; Nam GJ; Majumder R; Lim J; Lim SK; Seo YJ; Park YH
Probiotics Antimicrob Proteins; 2021 Apr; 13(2):315-326. PubMed ID: 32949011
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Probiotic Strains
Gulnaz A; Lew LC; Park YH; Sabir JSM; Albiheyri R; Rather IA; Hor YY
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931347
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR.
Shakeeb N; Varkey P; Hynse A; Mandlecha A
Inflammopharmacology; 2022 Jun; 30(3):883-894. PubMed ID: 35320494
[TBL] [Abstract][Full Text] [Related]
7. The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.
Shin JA; Oh S; Jeong JM
Phytomed Plus; 2021 Nov; 1(4):100058. PubMed ID: 35403084
[TBL] [Abstract][Full Text] [Related]
8. Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro.
Ma Q; Lei B; Chen R; Liu B; Lu W; Jiang H; Chen Z; Guo X; Wang Y; Zhang L; Chen Q; Li X; Yang Z
Chin Med; 2022 Apr; 17(1):40. PubMed ID: 35365215
[TBL] [Abstract][Full Text] [Related]
9. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.
Liang C; Hui N; Liu Y; Qiao G; Li J; Tian L; Ju X; Jia M; Liu H; Cao W; Yu P; Li H; Ren X
Phytomed Plus; 2021 May; 1(2):100027. PubMed ID: 35399819
[TBL] [Abstract][Full Text] [Related]
10. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.
Hakki S; Zhou J; Jonnerby J; Singanayagam A; Barnett JL; Madon KJ; Koycheva A; Kelly C; Houston H; Nevin S; Fenn J; Kundu R; Crone MA; Pillay TD; Ahmad S; Derqui-Fernandez N; Conibear E; Freemont PS; Taylor GP; Ferguson N; Zambon M; Barclay WS; Dunning J; Lalvani A;
Lancet Respir Med; 2022 Nov; 10(11):1061-1073. PubMed ID: 35988572
[TBL] [Abstract][Full Text] [Related]
14. Lactic acid bacteria feeding reversed the malformed eye structures and ameliorated gut microbiota profiles of Drosophila melanogaster Alzheimer's disease model.
Liu G; Tan FH; Lau SA; Jaafar MH; Chung FY; Azzam G; Liong MT; Li Y
J Appl Microbiol; 2022 Apr; 132(4):3155-3167. PubMed ID: 32640111
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632
[TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
17. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice.
Kumaki Y; Day CW; Bailey KW; Wandersee MK; Wong MH; Madsen JR; Madsen JS; Nelson NM; Hoopes JD; Woolcott JD; McLean TZ; Blatt LM; Salazar AM; Smee DF; Barnard DL
Antivir Chem Chemother; 2010 Mar; 20(4):169-77. PubMed ID: 20231782
[TBL] [Abstract][Full Text] [Related]
20. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
